We are dedicated to realizing the potential of natural killer (NK) cells for the treatment of cancer. Our proprietary technology is designed to harness the power of these important pathogen-fighting immune cells and is uniquely capable of enhancing their ability to search and destroy tumor cells. Our focus is to enhance the power, applicability and tolerability of cell therapy by developing next generation cell therapies that leverage the inherent pathogen fighting power of NK cells.
Find locations served, office locations
- Business Type:
- Industry Type:
- Market Focus:
- Nationally (across the country)
Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.
While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited to a few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
Our Vision and Mission
- OUR VISION | To be the leading company delivering innovative, accessible cell therapies for cancer patients, their caregivers and families
- OUR MISSION | We strive to discover, develop and deliver novel off-the-shelf NK cell therapy product candidates that have a profound impact on cancer patients